Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A

Date: May 20, 2019 Issue #:  1572Summary:  The FDA has approved emicizumab-kxwh (Hemlibra– Genentech), a subcutaneously injected, factor IXa- and X-directed antibody, for routine prophylaxis to prevent or reduce bleeding episodes in patients with hemophilia A. Emicizumab is not recommended for treatment of bleeding.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Beriplex Eloctate emicizumab Hemlibra Hemophilia Source Type: research